Boston biotech recruits Sanofi’s US cancer research chief; Syndax in-licenses Allergan portfolio

→Boston-based Silicon Therapeutics has recruited Sanofi’s US cancer R&D chief Christopher Winter to come over and run the R&D side of the business. Silicon has advanced new tech focused on physics-based simulations, chemistry and disease biology. This is just the latest in a long lineup of pharma investigators making their way to the biotech world.

Briggs Morrison

Syndax $SNDX CEO Briggs Morrison has in-licensed a portfolio of preclinical, oral small molecule inhibitors of the interaction of menin with the mixed lineage leukemia protein from Vitae, a subsidiary of Allergan.

→ Four months after Neothetics $NEOT was forced to read last rites over its sole experimental drug, the biotech is offering a convenient shell for a reverse merger into the market for Evofem Biosciences. An investor is buying $20 million in shares as Evofem pursues a late-stage study for a vaginal contraceptive.

Chi-Med and AstraZeneca are touting some preliminary partial responses from their early-stage work on combos using Tagrisso and Iressa with the experimental c-MET drug savolitinib.

Gilead Sciences $GILD has promoted Alessandro Riva to executive vice president, oncology therapeutics, fast on the heels of acquiring Kite and its soon-to-be approved CAR-T drug.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 41,700+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Head of Business Development
Wren Therapeutics Boston, MA
Life Sciences Venture Professional
Northpond Ventures Washington, DC
Senior Drug Discovery Oncologist
Schrödinger New York, NY

Visit Endpoints Careers ->